<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4889">
  <stage>Registered</stage>
  <submitdate>27/02/2015</submitdate>
  <approvaldate>27/02/2015</approvaldate>
  <nctid>NCT02397005</nctid>
  <trial_identification>
    <studytitle>Study of the Tolerability and Pharmacokinetic of ZL-2102 With an Investigation of Food Effect in Healthy Male Subjects</studytitle>
    <scientifictitle>Randomized, Double-blind, Placebo-controlled Study of the Tolerability and Pharmacokinetics of Ascending Single and 14-day Repeated Oral Doses of ZL-2102 With a Pilot Investigation of Food Effect in Healthy Male Subjects</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ZL-2102-SAD/FED/MAD</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Obstructive Pulmonary Disease</healthcondition>
    <healthcondition>Asthma</healthcondition>
    <healthcondition>Idiopathic Pulmonary Fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Chronic obstructive pulmonary disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ZL-2102
Treatment: drugs - Placebo matching ZL-2102

Active Comparator: ZL-2102 - Planned to be administrated in an ascending manner: 5,20,60,150,300,500,750mg

Placebo Comparator: Placebo - Placebo matching ZL-2102


Treatment: drugs: ZL-2102
A selective and reversible inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS).

Treatment: drugs: Placebo matching ZL-2102


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Part1,ZL-2102-SAD: Safety as measured by Adverse Events</outcome>
      <timepoint>8 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Part2,ZL-2102-FED: Safety as measured by Adverse Events</outcome>
      <timepoint>15 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Part3,ZL-2102-MAD: Safety as measured by Adverse Events</outcome>
      <timepoint>21 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Peak Plasma Concentration (Cmax) of ZL-2102</outcome>
      <timepoint>48 hours</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Area under the plasma concentration versus time curve (AUC) of ZL-2102</outcome>
      <timepoint>48 hours</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Part1,ZL-2102-SAD: Safety as measured by Physical examination, body weight, hematology, biochemistry, urinalysis, vital signs and 12-lead ECG.</outcome>
      <timepoint>8 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part2,ZL-2102-FED: Safety as measured by Physical examination, body weight, hematology, biochemistry, urinalysis, vital signs and 12-lead ECG.</outcome>
      <timepoint>15 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part3,ZL-2102-MAD: Safety as measured by Physical examination, body weight, hematology, biochemistry, urinalysis, vital signs and 12-lead ECG.</outcome>
      <timepoint>21 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male subject, between 18 and 45 years of age inclusive.

          -  Body weight between 50.0 and 100.0 kg inclusive, body mass index (BMI) between 18.0
             and 30.0 kg/mÂ² inclusive.

          -  Certified as healthy by a comprehensive clinical assessment (detailed medical history
             and complete physical examination).

          -  Normal vital signs after 5 minutes resting in a semi recumbent position.

          -  Normal standard 12-lead ECG after 5 minutes resting in a semi recumbent position.

          -  Laboratory parameters within the normal range, or considered not clinically
             significant by the Investigator.

          -  Subject returns a negative result to the Serology,Urine drug screen and alcohol breath
             tests.

          -  Having given written informed consent prior to any procedure related to the study.

          -  Not under any administrative or legal supervision.

          -  Males must agree to use adequate contraception for the duration of the study and for 3
             months post completion of dosing.

          -  Subject agrees to the following study restrictions:

               1. Subject will not consume citrus fruits and their juices for 5 days before the
                  start of the study, and for the duration of the study.

               2. Subject will not consume alcohol, tea, coffee, chocolate, quinine or
                  caffeine-containing beverages from Day 1 and for the duration of the study.

               3. Subject will note smoke or use tobacco from Day 1 and for the duration of the
                  study.

               4. Subject will avoid intensive physical activity from Day 1 and for the duration of
                  the study.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Any history or presence of clinically relevant cardiovascular, pulmonary,
             gastrointestinal, hepatic, renal, metabolic, hematological, neurological,
             osteo-muscular, articular, psychiatric, systemic, ocular, or infectious disease, or
             signs of acute illness.

          -  Frequent headaches and/or migraine, recurrent nausea and/or vomiting (more than twice
             a month).

          -  Blood donation, any volume, within 2 months prior to Screening.

          -  Symptomatic postural hypotension, whatever the decrease in blood pressure, or
             asymptomatic postural hypotension defined by a decrease in systolic blood pressure =
             20 mmHg within 3 minutes when changing from the supine to the standing position.

          -  Presence or history of drug hypersensitivity, or allergic disease (excluding hay
             fever) diagnosed and treated by a physician.

          -  History or presence of drug or alcohol abuse (alcohol consumption &gt;40 grams per day).

          -  Smoking more than 5 cigarettes or equivalent per day, unable to stop smoking during
             the study.

          -  Excessive consumption of beverages with xanthine bases (&gt;4 cups or glasses per day).

          -  Any prescription medication within 14 days and any over the counter medication within
             7 days before Screening or within 5 times the elimination half-life or Pharmacodynamic
             half-life of that drug whichever is longest unless approved by both the Investigator
             and the Medical Monitor; any vaccination within the last 28 days. If necessary,
             paracetamol (acetaminophen) may be administered with the approval of the Investigator.

          -  Any subject who, in the judgment of the Investigator, is likely to be non-compliant
             during the study, or unable to cooperate because of a language problem or poor mental
             development.

          -  Receipt of any investigational study drug within 30 days prior to screening.

          -  Any subject who is the Investigator or any sub-investigator, research assistant,
             pharmacist, study coordinator, or other staff thereof, directly involved in the
             conduct of the protocol.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>120</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/08/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Linear Clinical Research Unit - Perth</hospital>
    <postcode> - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Zai Lab Pty. Ltd.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The first-in-man study are designed as below to assess safety, tolerability, and preliminary
      pharmacokinetics of ZL-2102.

        -  Double-blind randomized, placebo-controlled ascending single oral doses (Part 1,
           ZL-2102-SAD);

        -  Open-label, randomized, 2-sequence, 2-period, 2-treatment crossover (Part 2,
           ZL-2102-FED);

        -  Double-blind randomized, placebo-controlled, ascending repeated oral doses for 14 days
           (Part 3, ZL-2102-MAD).

      A total of 104 subjects will be enrolled.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02397005</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>